leadf
logo-loader
viewOpen Orphan PLC

Open Orphan subsidiary completes toxicology study of possible respiratory virus treatment

PrEP-001, administered via a once-daily nasal spray, is designed to help treat all circulating respiratory viruses including COVID-19, influenza and the common cold

Open Orphan PLC - Open Orphan subsidiary completes toxicology study of possible treatment for respiratory viruses

Open Orphan PLC (LON:ORPH) said PrEP Biopharm Limited, in which it owns a 62.6% stake, has completed a 12-week toxicology study for its novel pan-viral prophylactic asset, PrEP-001.

The pharma services firm said the animal model study provides safety data needed to move PrEP-001 into longer duration dosing in clinical studies, adding that PrEP Biopharm intends to move forward with a real-world, field trial that is aiming to validate the efficacy of PrEP-001 against all circulating respiratory viruses including coronavirus (COVID-19), influenza and the common cold.

READ: Open Orphan higher as it renews contract with global pharmaceutical client

PrEP-001 is a synthetic RNA ‘viral mimic’ which is designed to stimulate the body's innate immune response in the upper respiratory tract to stop respiratory viruses. The treatment candidate is designed to be administered via a once-daily nasal spray.

Open Orphan also said that it does not intend to invest any of its shareholders’ funds into the project but is instead working with the PrEP Biopharm management team to secure other sources of funding outside of the Open Orphan group.

"It is very encouraging to note PrEP Biopharm's progress towards the ultimate goal of validating the effectiveness of their one dosage nasal spray for key respiratory viruses like COVID-19, flu and the common cold. This safety data allows them to move into Phase 2b field studies and we are very excited that PrEP-001 could play a meaningful role in the current COVID-19 pandemic and future potential pandemics caused by new respiratory viruses", Open Orphan executive chairman Cathal Friel said in a statement.

Quick facts: Open Orphan PLC

Price: 28.5 GBX

AIM:ORPH
Market: AIM
Market Cap: £190.78 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Open Orphan to become '$1bln firm in very near future' after COVID-19 study...

Open Orphan PLC's (LON:ORPH) Cathal Friel talks to Proactive London's Katie Pilbeam about the world’s first COVID-19 characterisation study receiving approval from a specially convened Research Ethics Committee (REC).  This follows a contract received by the company’s subsidiary hVIVO...

2 weeks, 5 days ago

2 min read